Botanix Pharmaceuticals begins enrolling its canine-focused atopic dermatitis study in Australia

Botanix Pharmaceuticals Ltd CEO Vince Ippolito joined Proactive New York to discuss the ASX-listed group’s plans to enroll 45 dogs in three sites across Australia to treat atopic dermatitis in canines using its synthetic cannabidiol drug BTX 1204A.

Ippolito says a successful outcome of the study could lead to partnering opportunities for the group within the $750M animal health market, as well as back into another Phase2b study in humans for atopic dermatitis.